US High Growth Tech Stocks To Watch In April 2025

Over the last 7 days, the United States market has dropped 3.0%. In contrast to the last week, the market is up 7.5% over the past year and earnings are expected to grow by 14% per annum over the next few years. In this context, identifying high growth tech stocks involves looking for companies with strong innovation potential and robust financial health that can capitalize on anticipated earnings growth amidst fluctuating market conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 238 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Red Cat Holdings (NasdaqCM:RCAT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Red Cat Holdings, Inc. operates in the United States, offering a range of products, services, and solutions tailored for the drone industry, with a market cap of $503.43 million.

Operations: The company generates revenue primarily from its enterprise segment, which contributed approximately $16.47 million.

Red Cat Holdings, with a projected annual revenue growth of 77.4%, is navigating the high-growth tech landscape despite its current unprofitability. The company's strategic focus on innovative drone technologies, as evidenced by recent U.S. Government orders totaling $518,000 for their Edge 130 drones, underscores its commitment to expanding in defense and security sectors. Additionally, the appointment of Christian Koji Ericson as CFO could enhance financial strategies to support this growth. With earnings expected to surge by 82.45% annually and a new partnership with Palladyne AI Corp., Red Cat is poised to leverage AI advancements in drone operations, potentially setting a new standard in the industry’s technological evolution.

• Unlock comprehensive insights into our analysis of Red Cat Holdings stock in this health report.

• Review our historical performance report to gain insights into Red Cat Holdings''s past performance.

Progress Software (NasdaqGS:PRGS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Progress Software Corporation develops, deploys, and manages AI-powered applications and digital experiences both in the United States and internationally, with a market cap of $2.22 billion.

Operations: Progress Software generates revenue primarily through its development and management of AI-powered applications and digital experiences. The company operates internationally, leveraging advanced technology to enhance digital interactions.

Progress Software, despite its modest annual revenue growth of 6%, significantly outpaces the market with a projected earnings increase of 32% annually. This performance is underscored by a robust R&D commitment, reflected in recent enhancements like the Web Application Firewall for its MOVEit Cloud service, aligning with stringent PCI DSS 4.0 standards. The firm's strategic acquisitions and product innovations suggest a forward-looking approach to embedding advanced technologies within its offerings, potentially securing its position in competitive tech landscapes. Moreover, substantial share repurchases totaling $506 million since 2016 underline confidence in long-term value creation, coupled with leadership adjustments aiming to intensify AI integrations across operations.

• Navigate through the intricacies of Progress Software with our comprehensive health report here.

• Understand Progress Software's track record by examining our Past report.

Simulations Plus (NasdaqGS:SLP)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Simulations Plus, Inc. specializes in creating drug discovery and development software using AI and machine learning technologies, with a market capitalization of $492.67 million.

Operations: The company generates revenue through two primary segments: software, contributing $44.15 million, and services, accounting for $30.29 million.

Simulations Plus, a specialist in drug discovery and development software, is leveraging its strategic alliances and recent technological advancements to potentially enhance its market position. The collaboration with the Enabling Technologies Consortium aims to refine oral drug delivery systems, which could revolutionize predictive modeling in pharmaceuticals. This initiative underscores Simulations Plus' commitment to innovation, evidenced by a 14.3% annual revenue growth and an impressive forecast of 32.1% earnings growth per year. Additionally, the company's R&D strategy is robust, with significant investments aimed at advancing their GastroPlus platform—critical for maintaining competitive edge in the rapidly evolving tech landscape of healthcare simulations.

• Delve into the full analysis health report here for a deeper understanding of Simulations Plus.

• Gain insights into Simulations Plus' historical performance by reviewing our past performance report.

Taking Advantage

• Gain an insight into the universe of 238 US High Growth Tech and AI Stocks by clicking here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com